Explore
Validate
Learn
Other assayAntibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations
- Other assay [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MA1-7657 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- Transferrin Receptor Monoclonal Antibody (ICO-92)
- Antibody type
- Monoclonal
- Antigen
- Other
- Description
- MA1-7657 detects Transferrin receptor from human samples.
- Antibody clone number
- ICO-92
- Concentration
- 1 mg/mL
Submitted references Development of Tumor-Targeted Indocyanine Green-Loaded Ferritin Nanoparticles for Intraoperative Detection of Cancers.
Everolimus Nanoformulation in Biological Nanoparticles Increases Drug Responsiveness in Resistant and Low-Responsive Breast Cancer Cell Lines.
H-Ferritin-nanocaged olaparib: a promising choice for both BRCA-mutated and sporadic triple negative breast cancer.
Sitia L, Sevieri M, Bonizzi A, Allevi R, Morasso C, Foschi D, Corsi F, Mazzucchelli S
ACS omega 2020 Jun 2;5(21):12035-12045
ACS omega 2020 Jun 2;5(21):12035-12045
Everolimus Nanoformulation in Biological Nanoparticles Increases Drug Responsiveness in Resistant and Low-Responsive Breast Cancer Cell Lines.
Bonizzi A, Truffi M, Sevieri M, Allevi R, Sitia L, Ottria R, Sorrentino L, Sottani C, Negri S, Grignani E, Mazzucchelli S, Corsi F
Pharmaceutics 2019 Aug 2;11(8)
Pharmaceutics 2019 Aug 2;11(8)
H-Ferritin-nanocaged olaparib: a promising choice for both BRCA-mutated and sporadic triple negative breast cancer.
Mazzucchelli S, Truffi M, Baccarini F, Beretta M, Sorrentino L, Bellini M, Rizzuto MA, Ottria R, Ravelli A, Ciuffreda P, Prosperi D, Corsi F
Scientific reports 2017 Aug 8;7(1):7505
Scientific reports 2017 Aug 8;7(1):7505
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 1 HFn specific interaction with CC lines. TfR1 expressionof CC linestested by cytofluorimetry expressed as mean fluorescence intensity(a) and as percentage of positive cells (b). Cells immunodecoratedwith the anti-mouse secondary antibody conjugated with Alexa Fluor488 were used to set the gate on viable cells, on singlets, and theregion of positivity. (c) HFn-F binding with CCs. Cells wereincubated 2 h at 4 degC in PBS buffer and 0.3% BSA with differentamounts of HFn-F (20 and 100 mug/mL). Cells were processedfor flow cytometry using untreated cells to set the positive regionand the singlet gate. (d) Competition assay in HT-29 cells (high TfR1expression) incubated with 500 muL of HFn-F (20 mug/mL)at 4 degC for 2 h with or without an excess of unlabeled HFn (1 mg/mL) as competitor. Cells were then detached and treated for flowcytometry. Untreated cells have been used to set the singlet gateand the positive region. Data are reported as average +- S.D.of three independent experiments and expressed as panel (a), meanfluorescence intensity (M.F.I., x10 5 ); panel (b),percentage of cells in the positive region to HFn-F fluorescenceand; panel (c), relative fluorescence intensity (R.F.I., %).
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 5 HFn-ICGinteraction with TfR1 low CCs. (a-c)Representative flow cytometry plots showing cell binding with 20,50, and 100 mug/mL of HFn-ICG (light green, purple, andblue curves, respectively, black curves = control cells) after 2 hincubation at 4 degC. (d-f) Representative confocal microscopyimages of cells incubated with HFn-ICG for 2 h at 4 degCto evaluate binding and TfR1 colocalization (blue = cell nuclei stainedwith DAPI, cyan = cell membranes, green = HFn-ICG, and purple= alphaTfR1 antibody staining). (g-i) Cellular uptake ofHFn-ICG evaluated by IVIS analysis, after incubation at 37degC for different time points. Low TfR1 expressions lead to lowbinding, low uptake, and low colocalization with TfR1.
